Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07799544 in BRAF-Mutant Melanoma and Other Solid Tumors
NCT05538130Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2022
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of polfurmetinib in melanoma, solid tumor, glioma and 2 more (3 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events at 2 years and 4 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
polfurmetinib
03
Conditions
melanomasolid tumorgliomathyroid cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05538130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538130.